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Intellectual disability, autismspectrumdisorder, andepilepsyareprimeexamplesof neurodevelopmental dis-
orders that collectively affect a significant percentage of the world population. Recent technological break-
throughs allowed the elucidation of the genetic causes of many of these disorders. As neurodevelopmental
disorders are genetically heterogeneous, the development of rational therapy is extremely challenging. Fortu-
nately, many causative genes are interconnected and cluster in specific cellular pathways. Targeting a com-
mon node in such a network would allow us to interferewith a series of related neurodevelopmental disorders
at once. Here, we argue that the GABAergic system is disturbed in many neurodevelopmental disorders,
including fragile X syndrome, Rett syndrome, and Dravet syndrome, and is a key candidate target for thera-
peutic intervention. Many drugs that modulate the GABAergic system have already been tested in animal
models with encouraging outcomes and are readily available for clinical trials.Neurodevelopmental disorders, including autism spectrum dis-
order (ASD), intellectual disability (ID), and epilepsy are the
consequences of a disturbance of CNS development that pre-
sents clinically as impairments in personal, social, academic,
or occupational functioning. Technological breakthroughs—in
particular, the development of high-capacity sequencing ma-
chines—facilitated the discovery of an increasing number of
causative genes over the last few years (Coe et al., 2014; De
Rubeis et al., 2014; Gilissen et al., 2014; Iossifov et al., 2014).
The search has been particularly successful in the identification
of genes that underlie syndromic forms of neurodevelopmental
disorders, such as in patients with a combination of ASD, ID,
and epilepsy. For instance, the SCN2A gene was originally
considered an epilepsy gene, but in more recent studies, it
was also found mutated in patients with ASD and with ID
(Krumm et al., 2014). All gene identification studies demon-
strate a substantial heterogeneity in the genetic causes, and
it has been estimated that 1,500–2,000 genes are responsible
for ID alone (van Bokhoven, 2011). This means that, with very
few exceptions, only a limited number of patients with a caus-
ative mutation in the same gene have been identified. This
genetic heterogeneity frustrates attempts to develop rational
therapy for individual disorders and initiatives aimed at treat-
ment of neurodevelopmental disorders are lagging (Green
and Guyer, 2011).
Emerging evidence suggests that many of the genes respon-
sible for individual neurodevelopmental disorders cluster in a
relatively limited number of modules that operate in the same
molecular processes (Epi4K Consortium and Epilepsy Phe-
nome/Genome Project, 2013; Gilman et al., 2011; O’Roak
et al., 2012; Voineagu et al., 2011). The encoded proteins
converge on a relatively limited number of protein-protein inter-
action (PPI) networks, including those that are involved in synap-
tic functioning and in chromatin remodeling (De Rubeis et al.,
2014; Krumm et al., 2014). This network concept is relevant
with respect to the prospects for therapy, as interference witha pathway disturbed in a group of disorders might bring therapy
for rare neurodevelopmental disorders one step closer to reality.
In this Perspective, we argue that the GABAergic system is a
key pathway that is commonly disturbed in many neurodevelop-
mental disorders. We recently provided an overview how, in
fragile X syndrome, animal experiments led to the initiation of
clinical trials (Braat and Kooy, 2015). Here, we illustrate that, in
many more neurodevelopmental disorders, this key inhibitory
pathway is disturbed. We aim to encourage initiatives to set up
clinical trials with the appropriate drugs that are on or close to
the market, as we believe that targeting the GABAergic abnor-
malities may be an unique opportunity for treatment for this
type of disorder. Proper inhibitory GABAergic signaling is essen-
tial for normal neural circuit function (reviewed by Hu et al., 2014;
Ramamoorthi and Lin, 2011; Rudolph and Mo¨hler, 2014).
Although only present in a minority of neurons, diverse popula-
tions of GABAergic interneurons regulate themuchmore uniform
majority of excitatory neurons. If the inhibition is disturbed,
excessive excitation results in a disturbance in the excitatory/
inhibitory balance (E/I balance) and, consequently, in a dysfunc-
tion of cognitive processes.
GABAA Receptor Subunit Diversity Creates Unique
Opportunities for Selective Pharmacological
Modulation
GABAA receptors are ligand-gated receptors, permeable to
chloride and bicarbonate (Olsen and Sieghart, 2008). Functional
receptors consist of five subunits selected from 19 known recep-
tor subunits: a1–6, b1–3, g1–3, d, ε, q, p, and r1–3. This non-random
assembly results in a complex heterogeneity of GABAA receptor
subtypes, and each subtype has a distinct physiological and
pharmacological profile (D’Hulst et al., 2009; Mody and Pearce,
2004; Rudolph and Knoflach, 2011). The most prominent sub-
type in the brain comprises a1, bn, and g2 subunits (McKernan
and Whiting, 1996; Sieghart and Sperk, 2002). In several less
abundant subtypes, the g subunit can be replaced by a d, ε, orNeuron 86, June 3, 2015 ª2015 Elsevier Inc. 1119
Figure 1. GABAergic Synapse and Pharmacological Modulators
(A) Gamma aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the adult mammalian brain (Olsen and Sieghart, 2008). GABA is syn-
thesized from glutamate by the enzyme glutamic acid decarboxylase (GAD) (Erlander et al., 1991). Two isoforms of this enzyme exist: GAD67 encoded by
GAD1 and GAD65 encoded by GAD2. GABA is packed into presynaptic vesicles by vesicular GABA transporters (VGAT/SLC32A1) (Gasnier, 2004).
Following an action potential, GABA is released into the synaptic cleft by fusion of the vesicles to the cell membrane. Once released, GABA can interact
with two types of receptors: ionotropic GABAA receptors (Olsen and Sieghart, 2008) or metabotropic GABAB receptors (Bowery et al., 2002; Gassmann
and Bettler, 2012). The action of GABA is terminated by reuptake into the presynaptic neuron or a glial cell by GABA transporters (GAT1/SLC6A1, GAT3/
SLC6A11, BGT-1/SLC6A12, and GAT2/SLC6A13) or by diffusion from the synaptic cleft (Madsen et al., 2010). GABA is degraded by the enzyme GABA-
transaminase (GABA-T/ABAT) and converted to glutamate and succinic semialdehyde (SSA). The latter is used by the enzyme SSADH/ALDH5A1 to
generate succinate for the Krebs cycle (Rowley et al., 2012).
(B) During early development, GABAAR-mediated signaling is depolarizing due to high expression of NKCC1 and high intracellular chloride concentration.
(C) Due to an upregulation of KCC2, the intracellular chloride concentration decreases and GABAAR-mediated signaling becomes hyperpolarizing during
development. Putative therapeutic compounds are indicated in red.
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Distinct receptor subtypes have a specific regional, cellular,
and subcellular expression pattern (Olsen and Sieghart, 2008).
For instance, GABAA receptors that contain an a1–3, bn, and g2
subunit are mainly synaptic, whereas a4–6 and d-containing
receptors are mainly peri- or extrasynaptically located (Belelli
et al., 2009; Farrant and Nusser, 2005; Glykys and Mody,
2007). Synaptic receptors mediate fast phasic inhibition,
whereas extrasynaptic receptors produce persistent tonic inhibi-
tion. In contrast to the inhibitory action in the adult brain, GABAA
receptors are depolarizing and often excitatory during early
development (Figure 1B) (Ben-Ari, 2002). This is a consequence
of developmental changes in chloride homeostasis, tightly regu-
lated by the Na+-K+-2Cl co-transporter 1 (NKCC1/SLC12A2)
and the K+-Cl co-transporter 2 (KCC2/SLC12A5). The chloride
importer NKCC1maintains high intracellular chloride concentra-
tions in immature neurons. Consequently, activation of GABAA
receptors in these neurons results in chloride efflux and mem-
brane depolarization. During development, the expression of
the chloride exporter KCC2 is upregulated, with a concomitant
downregulation of NKCC1 (Figure 1C). This shift in balance be-
tween chloride importers and exporters results in a progressive
decrease in intracellular chloride concentration, which induces1120 Neuron 86, June 3, 2015 ª2015 Elsevier Inc.the excitation-inhibition switch in GABAA receptor-mediated
signaling.
Known Consequences of Genetic Variation in the
GABAergic System
There is clear evidence for the involvement of GABAA receptors
in neurodevelopmental disorders (Table 1). Mutations in the a1
subunit have been identified in patients suffering from early in-
fantile epileptic encephalopathy, juvenile myoclonic epilepsy,
and other types of seizure disorders (Carvill et al., 2014; Cossette
et al., 2002; Maljevic et al., 2006; Epi4K Consortium and Epilepsy
Phenome/Genome Project, 2013). Mutations in the b3 subunit
have been identified in children with absence epilepsy (Epi4K
Consortium and Epilepsy Phenome/Genome Project, 2013;
Tanaka et al., 2008). Other subunits in which mutations have
been identified in patients with various forms of epilepsy disor-
ders include the g2 and d subunits (Baulac et al., 2001; Dibbens
et al., 2004). In the Prader-Willi/Angelman syndromes, a pair of
neurodevelopmental disorders caused by the paternal and
maternal deletions, respectively, of a chromosomal region on
15q11–13, three genes encoding subunits of the GABAA recep-
tor are deleted. A reciprocal duplication of the same chromo-
somal region results in autism. A gene dosage imbalance of
Table 1. Association of Genetic Alterations in the GABAergic System with Disease Susceptibility
Gene Phenotype Phenotype OMIM Number Reference
GABRA1 Early infantile epileptic encephalopathy 615744 Carvill et al. (2014)
Dravet syndrome
Susceptibility to childhood absence epilepsy 611136 Maljevic et al. (2006)
Susceptibility to childhood absence epilepsy Cossette et al. (2002)
Mutations in patients with juvenile myoclonic
epilepsy, infantile spasms, febrile seizures/
idiopathic generalized epilepsy
– Cossette et al. (2002); Epi4K Consortium and
Epilepsy Phenome/Genome Project (2013)
GABRA2 Susceptibility to alcohol dependence 103780 Li et al. (2014)
GABRA4 Possible contribution to autism susceptibility 209850 Ma et al. (2005)
GABRA5 Deleted in Prader-Willi/Angelman syndrome 176270 –
105830
Association with panic disorder – Hodges et al. (2014)
GABRA6 Association with idiopathic generalized
epilepsy
– Prasad et al. (2014)
GABRB1 Infantile spasms/Lennox-Gastaut syndrome – Epi4K Consortium and Epilepsy Phenome/
Genome Project (2013)
Possible contribution to autism susceptibility – Ma et al. (2005)
GABRB2 De novo mutation in patient with intellectual
disability and epilepsy
– Srivastava et al. (2014)
Association with schizophrenia – Tsang et al. (2013)
GABRB3 Susceptibility to childhood absence epilepsy 612269 Tanaka et al. (2008)
Possible association with ASD – Chen et al. (2014); Warrier et al. (2013)
Missense mutation in infantile spasms and
Lennox-Gastaut syndrome
– Epi4K Consortium and Epilepsy Phenome/
Genome Project (2013)
Association with panic disorder – Hodges et al. (2014)
De novo mutation in patients with moderate/
severe ID
– Hamdan et al. (2014)
Deleted in Prader-Willi/Angelman syndrome 176270 –
105830
GABRG2 Generalized epilepsy with febrile seizures plus 611277 Baulac et al. (2001)
Familial febrile seizures
Susceptibility to childhood absence epilepsy 607681 Wallace et al. (2001)
GABRG3 Deleted in Prader-Willi/Angelman syndrome 176270 –
105830
GABRD Susceptibility to generalized epilepsy with
febrile seizures plus
613060 Dibbens et al. (2004)
Idiopathic generalized epilepsy
Susceptibility to juvenile myoclonic epilepsy
GAD1 Spastic quadriplegic cerebral palsy 603513 Lynex et al. (2004)
SLC6A1 Suggested pathogenic genes deleted in
patients with ID, epilepsy, and stereotypic
behavior
– Dikow et al. (2014)
SLC6A11
ABAT GABA transaminase deficiency 613163 Medina-Kauwe et al. (1999)
ALDH5A1 SSADH deficiency 271980 Reis et al. (2012)
SLC12A2 Bartter syndrome 601678 Simon et al. (1996)
SLC12A5 Variant associated with febrile seizures – Puskarjov et al. (2014)
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mental delay, autism, and other clinical features observed in
these contiguous gene syndromes in addition to the imprinting
defects. Sequence variants of unknown significance inGABRB2could possibly contribute to intellectual disability and epilepsy
(Srivastava et al., 2014). An association with autism has been
reported for SNPs in GABRA4 and an association with general-
ized epilepsy has been suggested for GABRA6 (Ma et al.,Neuron 86, June 3, 2015 ª2015 Elsevier Inc. 1121
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dence have been reported for SNPs in GABRA2 and GABRA6
(Li et al., 2014).
Both mutations in the GABA synthesis and transporter genes
have also been associated with disease. Recessive mutations
in GAD1 cause cerebral palsy, a posture or movement disorder
caused by a brain abnormality first evident at the stage of rapid
brain development (Lynex et al., 2004). GABA transaminase defi-
ciency, due tomutations in both copies of theABAT gene, results
in severe psychomotor retardation, hypotonia, hyperreflexia,
lethargy, refractory seizures, high-pitched cry, and electroen-
cephalogram (EEG) abnormalities (Medina-Kauwe et al., 1999).
An excess of GABA underlies succinic semialdehyde dehydro-
genase (SSADH) deficiency, a neurologic disorder characterized
by hypotonia, intellectual disability, ataxia, seizures, hyperkinetic
behavior, aggression, and sleep disturbances (Reis et al., 2012).
It is caused by recessive mutations in ALDH5A1, an enzyme
in the GABA degradation pathway, that result in an elevation
of gamma-hydroxybutyric acid (GHB) and GABA in the brain.
Mutations in the Na-K-Cl co-transporter NKCC1/SLC12A2
cause Bartter syndrome, a primarily nephrological syndrome
with neurological involvement (Baird et al., 2006). Although
only observed in a single pedigree, the R952H variant in the
K-Cl co-transporter KCC2/SLC12A5 is a bona fide candidate
for febrile seizures (Puskarjov et al., 2014). A microdeletion en-
compassing the GABA transporters SLC6A1 and SLC6A11 on
chromosome 3p25.3 results in intellectual disability, epilepsy,
and stereotypic behavior (Dikow et al., 2014).
The GABAergic System Can Be Influenced by
Pharmacological Compounds
GABAA receptors can be targeted by a wide variety of pharma-
cological compounds (Carver and Reddy, 2013; D’Hulst et al.,
2009; Rudolph and Knoflach, 2011). The majority of these
compounds binds to allosteric sites of the receptor. Well-known
allosteric modulators include the benzodiazepines, which have
anticonvulsant and anxiolytic effects. These drugs had their
reputation damaged because of adverse side effects that
include sedation, physical dependence, and abuse liability. In
later years, the functional properties of benzodiazepines were
allocated to distinct GABAA receptor subtypes, and it was
determined that the a1 subunits mediate the sedative effects,
while a2/3 subunits mediate the anxiolytic effects (McKernan
et al., 2000; Rudolph et al., 1999). L-838,417 and TPA-023 are
examples of candidate drugs that target the a2/3 subtypes selec-
tively (Rudolph and Knoflach, 2011; Rudolph and Mo¨hler, 2014).
A very different class of allosteric modulators is the neuroste-
roids or neuroactive steroids, which bind the neurosteroid bind-
ing site of the receptor (Carter et al., 1997; Carver and Reddy,
2013; Nohria and Giller, 2007). Neurosteroids interact with
both synaptic and extrasynaptic GABAA receptors, with a prefer-
ence for d-containing, extrasynaptic GABAA receptor subtypes.
Synthetic derivatives of the endogenous neurosteroid allo-
pregnalone, such as alphaxalone and ganaxolone (3a-hydroxy-
3b-methyl-5a-pregnan-20-one), are available (Nohria and Giller,
2007). Additional candidate drugs include gaboxadol (also
known as THIP), a GABA-mimetic and superagonist at extrasy-
naptic d-containing GABAA receptors (Wafford and Ebert,1122 Neuron 86, June 3, 2015 ª2015 Elsevier Inc.2006). RO4938581 and alpha5IA are inverse agonists of the a5
subunit, a subtype involved in cognition (Atack, 2008; Ballard
et al., 2009; Dawson et al., 2006).
Apart frommodulating the activity of the GABAergic systemby
interfering directly with the receptor, pharmacological com-
pounds can also interfere with synaptic GABA concentrations
(Figure 1A). Tiagabine is a GABA reuptake inhibitor that specif-
ically blocks the GABA transporter GAT1 (Madsen et al., 2010).
Vigabatrin is an irreversible inhibitory of GABA-T, thus blocking
GABA catabolism (Rowley et al., 2012). Immature GABAA recep-
tor signaling can be targeted with bumetanide, an inhibitor of
NKCC1,whichdecreases the intracellular chlorideconcentration.
As the subunits of the GABAA receptor are non-uniformly
distributed though the brain, the choice of drugs has an influence
on the brain region targeted. For instance, the a5 subunit is pre-
dominantly present in the hippocampus, and the subtype-selec-
tive compounds RO4938581 and alpha5IA will, therefore, mostly
act in that brain region, whereas tiagabine, for instance, will have
a much more evenly distributed effect. Depending on the char-
acteristics of the abnormalities of the GABAergic system abnor-
malities, different drugs can be applied.
What We Know about GABAergic Deficits in
Neurodevelopmental Disorders
Fragile X Syndrome
The primary characteristics of fragile X syndrome (Online Men-
delian Inheritance in Man [OMIM] ID number 300624), a frequent
form of inherited ID, include cognitive and behavioral problems,
facial dysmorphism, and macroorchidism (Hagerman, 2002).
Epileptic seizures are common (Musumeci et al., 1999). Fragile
X syndrome is associated with ASD in approximately half of
the cases (Harris et al., 2008; Kaufmann et al., 2004; Lewis
et al., 2006). Specific autistic features include gaze avoidance,
hand flapping, repetitive behaviors, and speech perseveration.
The disorder is caused by a dynamic, inactivating mutation in
the FMR1 gene (Verkerk et al., 1991). The encoded protein,
FMRP, is thought to interact with hundreds of neuronal mRNAs
(Ascano et al., 2012; Darnell et al., 2011; Suhl et al., 2014), and
its absence affects numerous molecular pathways in the cell
(Darnell and Klann, 2013).
Experimental Evidence from Animal Models for the
Involvement of the GABAergic System
An increasing number of studies in Fmr1 knockout mice, a
validated mouse model for the human disorder, support the hy-
pothesis of an impaired inhibitory, GABAergic system in fragile X
syndrome (reviewed by Braat and Kooy, 2015; Cea-Del Rio and
Huntsman, 2014; Paluszkiewicz et al., 2011). Age- and brain-re-
gion-dependent differential expression has been reported for
several GABAA receptor subunits and multiple other compo-
nents of the GABAergic system, including enzymes involved in
GABA synthesis (Gad1 and Gad2), GABA transporters (Slc6a1
and Slc6a11), an enzyme involved in GABA degradation
(Aldh5a1), and a targeting and clustering protein (Gphn). More-
over, altered phasic and/or tonic GABAA receptor-mediated
signaling has been observed in the subiculum, basolateral amyg-
dala, somatosensory cortex, and striatum. Decreased GABA
concentrations have been reported in several brain regions.
Interneuron subtype-specific neuroanatomical deficits have
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overall downregulation of the GABAergic system that is brain re-
gion and age dependent, a delayed excitation-inhibition switch
of GABAA receptors has been reported in the somatosensory
cortex of Fmr1 knockout mice from postnatal day 10 to postnatal
day 14 (He et al., 2014). The delayed GABA polarity switch in
Fmr1 knockout mice was paralleled by a higher NKCC1 expres-
sion in that period of development. Apart from the delay in the
permanent polarity switch in the second postnatal week, the
transient excitation-inhibition switch triggered by the maternal
hormone oxytocin, which causes an abrupt decrease in intracel-
lular chloride concentrations during delivery, is absent from
hippocampal CA3 pyramidal neurons of Fmr1 knockout mice
(Tyzio et al., 2014).
Preclinical Studies Highlight the Therapeutic Potential
of the GABAA Receptor
The GABAA receptor as a therapeutic target for fragile X syn-
drome was first postulated in 2007 (D’Hulst and Kooy, 2007). A
high-throughput screening of a library of 2,000 compounds in a
fragile X fly model for their ability to rescue the glutamate-
induced lethality in dfmr1 mutants demonstrated that three of
the nine lead compounds were modulators of the GABAergic
system (Chang et al., 2008). These include GABA itself, nipecotic
acid, a GABA reuptake inhibitor, and creatinine, a GABAA recep-
tor activator. Each of these compounds was able to correct spe-
cific phenotypes of dfmr1-deficient Drosophila, such as b-lobe
crossing in the mushroom body and diminished courtship
behavior. This paper provided the first experimental evidence
that increasing GABAergic signaling—either directly through
stimulation of GABAA receptors (GABA and creatinine) or indi-
rectly by increasing synaptic GABA concentrations (nipecotic
acid)—is able to restore the abnormalities observed in a fly
model. GABA itself is not suitable for treatment in mice, as it
does not cross the blood-brain barrier. Subsequent studies
with the GABA-mimetic gaboxadol in Fmr1 knockout mice
demonstrated a correction of hyperactivity as measured in the
open field and modulation of altered sensorimotor gating,
measured as increased prepulse inhibition after acute treatment
(Olmos-Serrano et al., 2011).
Acute treatment of Fmr1 knockout mice with ganaxolone
completely prevented audiogenic seizures (Heulens et al.,
2012) and corrected repetitive/perseverative behavior in a
marble-burying assay in a dose-dependent manner and partially
corrected prepulse inhibition abnormalities (Braat et al., 2015).
Moreover, acute maternal pre-treatment with the NKCC1 antag-
onist bumetanide was able to restore the excitation-inhibition
switch in neonatal Fmr1 knockout mice and corrected electro-
physiological and behavioral phenotypes (Tyzio et al., 2014).
Rett Syndrome
Patients with Rett syndrome (OMIM ID number 312750), an ASD
caused by loss-of-function mutations of the methyl-CpG-bind-
ing protein 2 (MECP2) gene on Xq28, may develop normally until
6–18 months of age, after which a regression phase occurs,
accompanied by a loss of acquired skills (reviewed by Chahrour
and Zoghbi, 2007; Neul et al., 2010). Associated autistic-like fea-
tures include social withdrawal, lack of eye contact, and indiffer-
ence to the surrounding environment, but the clinical spectrum
of the disorder also involves intellectual disability, epileptic sei-zures, breathing abnormalities, and hypotonia. Following the
identification of MECP2 as the causal gene (Amir et al., 1999),
a variety of mouse models was generated (reviewed by Calfa
et al., 2011; Katz et al., 2012), with the Mecp2tm1.1Bird (deletion
of a fragment containing exons 3 and 4) (Guy et al., 2001) and
Mecp2tm1.1Jae (exon 3 deletion) (Chen et al., 2001) models
being most commonly used. These mouse models recapitulate
many features of Rett syndrome, including cognitive and behav-
ioral aberrations, motor impairments, breathing abnormalities,
and premature lethality. Electrophysiological recordings in
Mecp2tm1.1Bird mice show decreased basal inhibitory rhythmic
activity in the CA3 region of the hippocampus (Zhang et al.,
2008) and decreased phasic inhibition in the ventrolateral me-
dulla (Medrihan et al., 2008) and in the locus coeruleus (Jin
et al., 2013).MeCP2 deficiency in the thalamus leads to opposite
changes in excitatory and inhibitory neurons, with reduced
miniature inhibitory postsynaptic current (mIPSC) frequency in
excitatory ventrobasal complex neurons and increased mIPSC
frequency in inhibitory reticular thalamic nucleus neurons (Zhang
et al., 2010). Moreover, several components of the GABAergic
system were differentially expressed due to MeCP2 deficiency.
A significant reduction was observed in a2 and a4 subunit
mRNA expression in the ventrolateral medulla, without changes
in the other a, b, and g subunits (Medrihan et al., 2008). The
mRNA and protein expression levels of vesicular inhibitory amino
acid transporter/GABA vesicular transporter (VIAAT/VGAT)
(Slc32a1) were also reduced in this brain region. In the thalamus,
VIAAT/VGAT immunostaining was decreased in excitatory ven-
trobasal complex neurons and increased in inhibitory reticular
thalamic nucleus neurons in the thalamus (Zhang et al., 2010).
El-Khoury et al. (2014) reported brain-region- and age-depen-
dent alterations in the GABAergic system of MeCP2-deficient
mice, including decreased GABA levels in the hippocampus,
substantia nigra pars reticulata, and cerebellum; altered mRNA
expression; and protein expression of GABAergic markers in
the caudate putamen, ventral midbrain, and hippocampus.
Recently, Tomassy et al. (2014) reported subtype-specific
morphological alterations in neocortical interneurons. Loss of
Mecp2 from GABAergic neurons in Viaat-Mecp2/y mice reca-
pitulates many features of Rett syndrome, including premature
lethality, motor dysfunction, breathing abnormalities, impaired
spatial memory, stereotypic behavior, altered social interactions,
and sensorimotor gating deficits (Chao et al., 2010). Mice with a
forebrain-specific and GABAergic-neuron-specific deletion of
Mecp2 (Dlx5/6-Mecp2/y) recapitulated a subset of Rett charac-
teristics such asmotor dysfunction, stereotypic behavior, altered
social interactions, and sensorimotor gating deficits.
These murine findings are supported by abnormalities in the
GABAergic system detected in Rett syndrome patients. While
GABA concentrations in the cerebrospinal fluid of girls with
Rett syndrome appeared unaltered (Perry et al., 1988), GABAA
receptor binding was significantly increased in the caudate at a
young age, as measured by 3H-muscimol receptor autoradio-
graphy on postmortem basal ganglia slices (Blue et al., 1999).
On the other hand, in vivo 123I-iomazenil single-photon emission
computed tomography (SPECT) scans revealed decreased
GABAA receptor binding in the frontotemporal cortex of adult
female Rett syndrome patients (Yamashita et al., 1998).Neuron 86, June 3, 2015 ª2015 Elsevier Inc. 1123
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brospinal fluid of young Rett syndrome patients showed
decreased KCC2 protein expression and decreased KCC2/
NKCC1 ratio, reminiscent of immature GABAA receptor function
(Duarte et al., 2013) (Figure 1).
Preclinical studies in Rett mouse models revealed improve-
ments in several domains after pharmacological correction of
the GABAergic system deficits. The lifespan of Mecp2tm1.1Bird
male mice was significantly extended following chronic inhibi-
tion of GABA reuptake with tiagabine (El-Khoury et al., 2014).
Respiratory problems in adult Mecp2tm1.1Bird mice were signif-
icantly reduced by enhancing GABAA receptor-mediated
signaling, either by blocking GABA reuptake or by positive
allosteric modulation of the GABAA receptor itself (Abdala
et al., 2010). More specifically, blocking the GABA transporter
GAT-1 with NO-711 reduced the occurrence of apnea and
corrected respiratory cycle irregularity in Mecp2+/ and
Mecp2/y mice and reduced periodic breathing in Mecp2+/
mice. Treatment with a positive allosteric modulator, either
diazepam or L-838,417, reduced the occurrence of apnea,
corrected respiratory cycle irregularity, and reduced periodic
breathing in Mecp2+/ mice. In addition, acute treatment
with the benzodiazepine midazolam abolished respiratory
problems in young Mecp2tm1.1Bird male mice (Voituron and
Hilaire, 2011).
Dravet Syndrome
Patients with Dravet syndrome or severe myoclonic epilepsy of
infancy (SMEI; OMIM ID number 607208) suffer from multiple
types of refractory seizures during the first year and from myoc-
lonus, atypical absence seizures, and partial seizures later on
(Dravet, 2011). Common comorbid features include intellectual
disability; behavioral problems such as hyperactivity; and
autistic features, in combination with motor problems, including
poor fine motor abilities, uncoordinated movements, hypotonia,
and ataxia (Dravet, 2011; Li et al., 2011). The majority of patients
have a de novo heterozygous loss-of-function mutation in the
SCN1A gene, which encodes for the a1 subunit of the voltage-
gated sodium channel NaV1.1 (Claes et al., 2001, 2009; Lossin,
2009).
Heterozygous knockout Scn1a mice (Scn1atm1Wac) display
seizures and other characteristics compatible with the symp-
toms observed in patients, including premature death. A sec-
ond mouse model containing a heterozygous loss-of-function
nonsense mutation in the Scn1a gene (R1407X in exon 21
of Scn1a, Scn1atm1.1Kzy/Scn1aRX1407X) exhibits similar charac-
teristics (Ogiwara et al., 2007). While NaV1.1 channels are
expressed in both excitatory and inhibitory neurons, electro-
physiological recordings indicated that Scn1a haploinsuffi-
ciency (Scn1atm1Wac) specifically reduces Na+ currents and
impairs action potential firing in GABAergic neurons in the hip-
pocampus and cerebellum (Kalume et al., 2007; Ogiwara et al.,
2007; Yu et al., 2006). The resulting excitation-inhibition imbal-
ance and hyperexcitability potentially relates to the epileptic
phenotype in the hippocampus (Yu et al., 2006) and the ataxic
phenotype in the cerebellum (Kalume et al., 2007). Sponta-
neous IPSC (sIPSC) frequency was decreased, and sponta-
neous excitatory postsynaptic current (sEPSC) frequency was
increased in the hippocampal CA1 region and the prefrontal1124 Neuron 86, June 3, 2015 ª2015 Elsevier Inc.cortex of Scn1a+/ slices compared to wild-type slices (Han
et al., 2012). Further support for the prominent involvement of
the GABAergic deficits in Dravet syndrome was obtained
from a conditional mouse model with Scn1a exclusively inacti-
vated in the forebrain GABAergic neurons with the aid of a Dlx1/
2-Cre promoter (Cheah et al., 2012; Han et al., 2012). These
Dlx1/2-Scn1a+/ mice phenocopy the global Scn1a+/ mu-
tants, displaying premature death, spontaneous and tempera-
ture-dependent seizures (Cheah et al., 2012), elevated locomo-
tor activity in the open field, increased anxiety-like behavior in
the open field and elevated plus maze, increased circling
behavior, social interaction deficits in the open field social inter-
action test and three-chamber social preference test, and
impaired contextual fear memory (Han et al., 2012). Similarly,
specific/selective Scn1a haploinsufficiency in parvalbumin-
positive interneurons in the neocortex and hippocampus using
the Ppp1r2-Cre mouse line resulted in spontaneous, tempera-
ture-dependent, and flurothyl-induced seizures (Dutton et al.,
2013).
Acute treatment of Scn1a+/ mice (Scn1atm1Wac) with a low
non-sedative and non-anxiolytic dose of the benzodiazepine
clonazepam completely rescued impaired social behaviors in
the open field social interaction test and the three chamber
test, as well as the impairment in context-dependent fear
memory (Han et al., 2012). At the electrophysiological level,
clonazepam increased sIPSC amplitude, which leads to a
decrease in sEPSC frequency. Chronic treatment with a combi-
nation of the clonazepam and the GABA reuptake inhibitor
tiagabine had a synergistic effect on seizure control (Oakley
et al., 2013).
GABAergic System Involvement in Additional
Neurodevelopmental Disorders
Apart from fragile X, Rett, and Dravet syndromes mentioned
earlier, evidence is accumulating that the GABAergic system is
affected in other neurodevelopmental disorders. In neurofibro-
matosis type 1, caused by absence of a functional copy of the
NF1 gene and associated with cognitive deficits, knockout
mousemodel studies suggested that increasedGABA-mediated
inhibitory neurotransmission is the neural mechanism underlying
these deficits and that these deficits could be rescued by phar-
malogical interference (Cui et al., 2008). Tourette syndrome is a
disorder of unknown genetic etiology that is associated with
tics but also with attention deficit/hyperactivity disorder and
obsessive-compulsive disorder. Abnormalities in brain GABA
and, consequently, a loss of inhibition in these patients have
been observed (Hallett, 2015). The largest isoform of ANK3, a
gene implicated in many neurodevelopmental and neuropsychi-
atric disorders, is involved in GABAergic synapse stability
through interaction with a GABA-receptor-associated protein
and through inhibition of receptor endocytosis (Tseng et al.,
2015). In Down syndrome, caused by a dosage imbalance of
the genes on chromosome 21, dampening the excessive
GABAergic inhibition with an a5-specific inverse agonist has
been demonstrated to correct the cognitive disabilities in a
mouse model (Rudolph and Mo¨hler, 2014). However, autism,
of unknown etiology, has been hypothesized to be the conse-
quence of a disturbance in the E/I balance, and more recently,
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been demonstrated postmortem in the frontal cortex of patients
(Fatemi et al., 2014; Rubenstein and Merzenich, 2003). In
the brains of schizophrenia patients, a decreased amount of
NMDA (N-methyl-D-aspartic) receptor expression has been
observed specifically in GABAergic neurons that is associated
with a decrease in expression of the two GABA-synthesizing en-
zymes and several other components of the GABAergic system
(Fatemi and Folsom, 2014).
While in each of these named disorders additional molecular
pathways are affected—for instance, in fragile X syndrome,
additional disturbed pathways include the endocannabinoid,
glutamatergic, and muscarinic acetylcholine receptor systems,
glycogen synthase kinase-3, extracellular signal-related kinase
(ERK), mammalian target of rapamycin (mTOR), and p21-acti-
vated kinase signaling pathways and extracellular matrix metal-
loproteinase 9 (reviewed by Braat and Kooy, 2014)—the involve-
ment of the GABAergic pathway is the only pathway involved in
the pathophysiology of all named neurodevelopmental disor-
ders. The mechanism underlying this disturbance is unknown
and may differ between disorders. In fragile X syndrome, direct
binding of the fragile X protein to specific subunits of the
GABAA receptor has been demonstrated (Braat et al., 2015;
Miyashiro et al., 2003), but it is unclear how and even if this bind-
ing causes the expression dysregulation.
Therapeutic Trials Based on GABAergic Treatment
Inspired by the preclinical test results in rodents, several trials
in patients with drugs that interfere with the GABAergic system
in patients have been set up. The efficacy of stiripentol in Dra-
vet patients has been demonstrated in two placebo-controlled
trials, as an add-on treatment in combination with valproate
and clobazam (Chiron et al., 2000). Stiripentol has multiple
mechanisms of action, one of those being a direct allosteric
modulator of GABAA receptors (Fisher, 2009; Quilichini et al.,
2006). It potentiates both phasic and tonic inhibition and binds
at an allosteric site of the GABAA receptor, distinct from the
benzodiazepine- and the neurosteroid-binding sites (Fisher,
2009; Grosenbaugh and Mott, 2013; Quilichini et al., 2006).
It acts at all GABAA receptor subtypes but has the highest ac-
tivity at a3- and d-containing GABAA receptors. A two-center,
phase II clinical trial with ganaxolone in fragile X patients is
currently ongoing (https://www.clinicaltrials.gov [NCT]: ID num-
ber NCT01725152). Ganaxolone is a synthetic neurosteroid
that is orally active, lacks hormonal side effects based on
3b-methyl substitution, and has limited adverse effects (Carter
et al., 1997; Monaghan et al., 1997). It has already been evalu-
ated for its efficacy in various types of epilepsy in children and
adults (Kerrigan et al., 2000; Laxer et al., 2000; Pieribone et al.,
2007). A randomized, double-blind, placebo-controlled cross-
over study aims to evaluate the efficacy of ganaxolone on
aberrant behavior—in particular, with regard to anxiety and
attention—in children with fragile X syndrome, with the Clini-
cian’s Global Impression-Improvement (CGI-I) as the primary
outcome measure dysfunction (NCT: NCT01725152). In adults
with Down syndrome, Hoffman-La Roche is running a clinical
trial to test whether their compound RG1662 (related to
RO4938581), an inverse agonist of the a5 subunit, can reducethe severity of cognitive dysfunction (NCT: NCT01436955).
The Erasmus Medical Center in Rotterdam is recruiting NF1 pa-
tients for inclusion in a trial to investigate the effect of lamotri-
gine on cognition (NCT: NCT02256124). This drug is an agonist
of the hyperpolarization-activated, cyclic-nucleotide-gated
channel 1 (HCN1) that is compromised predominantly in inhib-
itory interneurons of an animal model of the disorder. Lamotri-
gine has been demonstrated to correct the electrophysiological
and the cognitive deficits in NF1 knockout mice (Omrani et al.,
2015).
AZ7325/AZD7325 is an a2/a3-selective GABAA receptor-pos-
itive modulator that is currently evaluated in a phase II random-
ized, double-blind, placebo-controlled trial for its efficacy on so-
cial disability in young adults with ASD (NCT: NCT01966679).
The primary outcome measure for this study is the effect of
the compound on EEG patterns. In addition, side effects and
measures of attention and learning will be monitored. The para-
doxical effects of benzodiazepines on specific features, such as
anxiety in some autism patients (Marrosu et al., 1987), led to the
hypothesis that GABAA receptors are excitatory rather than
inhibitory in a subgroup of patients. These findings inspired a
randomized controlled trial with bumetanide in children with
autism or Asperger’s syndrome (Lemonnier et al., 2012). The
diuretic bumetanide is clinically used to treat hypertension,
broncho-pulmonary dysplasia, nephritic syndromes, or heart
congestions. Significant improvements were observed in the
Childhood Autism Rating Scale (CARS) and the Clinical Global
Impressions (CGI), and Autism Diagnostic Observation Sched-
ules (ADOS) in a subgroup of patients with a mild phenotype. A
phase I trial to study the pharmacokinetics and safety of bume-
tanide in newborns with refractory seizures is currently ongoing
(NCT: NCT00830531).
Thus far in this Perspective, we have focused on the GABAA
receptor abnormalities. A single trial with arbaclofen (STX209),
a GABAB receptor agonist, has been carried out in fragile X syn-
drome patients, inspired by a positive evaluation of the efficacy
of this compound in animal studies (Henderson et al., 2012). Me-
tabotropic GABAB receptors are assembled as heterodimers,
containing a GABAB1 and a GABAB2 subunit (Bowery et al.,
2002; Gassmann and Bettler, 2012). Through inhibition of neuro-
transmitter release at the presynaptic glutamatergic terminal,
GABAB receptor agonists are thought to dampen excess excit-
atory mGluR signaling in Fmr1 knockout mice. It had been hy-
pothesized that, by inhibiting this specific type of glutamatergic
signaling, many of the symptoms of fragile X syndrome could be
corrected (Bear et al., 2004). Disappointingly, in a randomized
double-blind, placebo-controlled crossover study in children
and adults with fragile X syndrome, no significant improvements
were detected in the primary endpoint, the Aberrant Behavior
Checklist-Irritability (ABC-I) (Berry-Kravis et al., 2012). However,
post hoc analysis with the ABC-Social Avoidance scale specif-
ically adapted for fragile X syndrome, revealed significant
improvements in the entire study population. In addition, in a
subgroup of patients with more severe social impairments, sig-
nificant improvements were observed on the Vineland II-Social-
ization scale, on the ABC-Social Avoidance scale, and on all
global measures. It remains difficult for us to comment on the
meaning of the post hoc analysis. Because the Food and DrugNeuron 86, June 3, 2015 ª2015 Elsevier Inc. 1125
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ori what it will do in the patient population and requires the con-
ducted trials to determine whether the drug delivers the pre-
dicted results, this trial is officially registered as a failure. The
reason for this attitude is the marginal significance that may be
associated with the post hoc analysis and, consequently, the
risk of reporting false-positive results. On the other hand, one
can argue that, in the case of multisystem disorders such as
fragile X syndrome, the precise clinical effects of the drug under
study may be hard to predict and can only be identified once a
pilot study has been completed. It is, therefore, a pity that the
open label extension study with STX209 had to be terminated
due to resource limitations from Seaside Therapeutics, the phar-
maceutical company involved (NCT: NCT01555333).
Which Symptoms Can Be Targeted by Pharmalogical
Interference?
So far, we have illustrated that mutations in components of the
GABAergic system result in a range of neurodevelopmental dis-
orders and that, at the same time, in many neurodevelopmental
disorders, disturbances in the GABAergic system are apparent.
Reported trials with GABAergic drugs in animal models reported
correction of some behavioral abnormalities. Trials in patients
have been initiated and some more are in the planning stages,
but what can we expect from these trials in patients? While neu-
rodevelopmental disorders, by definition, result from a distur-
bance during brain development and connections that have
been miswired during developments are considered irreversible,
recent studies in animal models suggest that it is possible to
reverse certain deficits associated with these disorders in
adults by genetic or pharmacological manipulations (reviewed
in Castre´n et al., 2012). An example is the fragile Xmousemodel.
Conditional knockouts that allowed the Fmr1 gene to be
switched on and off at selected times during development
showed that most of the symptoms of the animal model could
be reversed by reactivation of the gene in adulthood (David
Nelson, personal communication).
There is clear evidence for the involvement of GABAA recep-
tors in epilepsy, anxiety, and insomnia (Table 1), and we would
expect improvements in these disorders, provided that drugs
are able to compensate for the alterations in the GABAergic sys-
tem in the patients. Cognition is predominantly associated with
alterations in the level of a5 subunits (Dawson et al., 2006).
Cognition enhancers in the form of a5 enhancers have shown
an effect in animal models but have not been tested in humans
as yet (Rudolph and Mo¨hler, 2014). As stated earlier, RG1662
is now in a clinical trial with, as a primary aim, the improvement
of cognition in Down syndrome patients.
Pessimists will argue that chances of a successful completion
of this specific trial or, in fact, any of the ongoing trials are slim:
more than 80% of treatments that were shown effective in
mouse studies failed in patients, despite the fact that the animal
studies necessary to assess drug safety and therapeutic poten-
tial were successful (Perrin, 2014). There has been much specu-
lation on the origin of this discrepancy. A publication bias toward
positive results and a lack of well-designed preclinical experi-
ments are most frequently assumed to be responsible for the
high failure rate. We would like to add to these arguments that,1126 Neuron 86, June 3, 2015 ª2015 Elsevier Inc.in some cases, clinical trials are inspired based on the results
generated in a single laboratory. Given the variability in test re-
sults that may occur between laboratories even after rigorous
standardization of the test battery (Crabbe et al., 1999), an inde-
pendent experimental confirmation in a second laboratory will, in
our opinion, reduce the percentage of failed human trials.
Another possible cause of the high failure rate is the lack of
confirmation of the animal study results in the patient. Due to
the scarcity of postmortem materials, this can only be realisti-
cally archived using imaging techniques. Using magnetic reso-
nance spectroscopy (MRS) to measure GABA levels in patients
with NF1, Violante et al. (2013) demonstrated a reduced quantity
of this inhibitory neurotransmitter in the visual cortex. [11C]fluma-
zenil positron emission tomography (PET) was used to demon-
strate a reduced binding of GABA to its receptor in patients
with SSADH deficiency (Pearl et al., 2009). The same technique
was used to demonstrate a reduction in the total amount of
GABAA receptors in both the Prader-Willi and fragile X syn-
dromes (C. D’Hulst, I. Heulens, N. Van der Aa, K. Goffin, M.
Koole, K. Porke, L. Rooms, M. Van De Velde, W. Van Paesschen,
H. Van Esch, K. Van Laere, and R.F.K., unpublished data;
Lucignani et al., 2004).
The Road Ahead
There is an immediate need for the development of therapy for
neurodevelopmental disorders. Due to the genetic heterogene-
ity observed, targeted treatment aimed at interference with
pathways commonly disturbed in multiple disorders might be
the only realistic option. We have highlighted in this perspec-
tive (1) that the GABAergic system is affected in multiple neuro-
developmental disorders, (2) that the GABAA receptor hetero-
geneity and its well-known pharmacological properties
provide a unique opportunity for targeted therapy, and (3)
that interference with the GABA receptor has the potential to
interfere with aspects of behavioral and even cognitive abnor-
malities in patients. Results of preclinical trials in several of
these disorders have shown encouraging results and raised
hopes for treatment in patients. Trials have been successfully
conducted in human patients with Dravet syndrome and are
ongoing in fragile X syndrome patients and in patients with
several other types of ASD. The outcome of these trials is
eagerly awaited.
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